Journal Article

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Xu, Yang, Wu, Mengmeng, Ou, Qiuxiang, Chen, Zhiming, Zhang, Zhenlong, Hou, Peifeng, Wang, Chunyue, Wang, Song, Sun, Yulan, Shao, Yang, Liu, Hong

2022

Overview

Background RET fusions are rare oncogenic drivers in non-small cell lung cancer (NSCLC). While activating RET rearrangements are found in NSCLC patients harboring epidermal growth factor receptor ( EGFR ) genetic alterations at resistance to EGFR inhibitors, the extent to which co-occurring genomic alterations exist and how they might affect prognosis or therapy response is poorly understood. Methods Targeted next-generation sequencing (NGS) was used to assess 380 baseline patients with primary RET fusions and 71 EGFR -mutated NSCLC patients who acquired RET fusions after developing resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Results Primary RET fusions were more likely associated with females and younger age, with KIF5B being the predominant fusion partner. In baseline patients, both SMAD4 (5.3% vs. 0.0%, P  = 0.044) and MYC copy-number gain variants (6.9% vs. 0.0%, P  = 0.009) were more frequently co-mutated with KIF5B-RET than CCDC6-RET . By contrast, CDKN2A (11.3% vs. 2.4%, P  = 0.003) mutations were significantly enriched in CCDC6-RET -rearranged baseline patients. A significant increase in the proportion of CCDC6-RET was observed in acquired RET -rearranged patients (47.3% vs. 22.5%, P  < 0.001). The median progression-free survival (PFS) of patients harboring RB1 and TP53 double-mutations (5.5 vs. 10.0 months, P  = 0.020) or ERBB2 amplification (5.6 vs. 10.0 months, P  = 0.041) was significantly shorter than the wild-type counterparts. Moreover, we identified that RET fusions were more likely associated with acquired resistance (AR) to third-generation EGFR-TKIs than previous generations of EGFR-TKIs. Conclusions In conclusion, we depicted the mutational profiles of NSCLC patients who harbor RET fusions at baseline or after resistance to EGFR-TKIs. Furthermore, our results suggest that RET fusions mediate secondary resistance to third-generation EGFR-TKIs and might be associated with poor prognosis in patients with NSCLC.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Biomedical and Life Sciences / Biomedicine / CCDC6 / Cell growth / Combination strategies / Drug resistance / Drug therapy / EGFR-TKI / Epidermal growth factor / Epidermal growth factor receptors / ErbB-2 protein / FDA approval / Genetic aspects / Genomes / KIF5B / Kinases / Lung cancer / Lung cancer, Non-small cell / Medical prognosis / Medicine/Public Health / Metastasis / Mutation / Myc protein / Next-generation sequencing / Non-small cell lung carcinoma / Noncanonical RET fusion / NSCLC / p53 Protein / Patient outcomes / Patients / Plasma / Prognosis / Response rates / Ret protein / RET rearrangement / Risk factors / Smad4 protein / Small cell lung carcinoma / Testing laboratories / Tyrosine kinase inhibitors